Niimi, Yoshiki
Janelidze, Shorena
Sato, Kenichiro
Tomita, Naoki
Tsukamoto, Tadashi
Kato, Takashi
Yoshiyama, Kenji
Kowa, Hisatomo
Iwata, Atsushi
Ihara, Ryoko
Suzuki, Kazushi
Kasuga, Kensaku
Ikeuchi, Takeshi
Ishii, Kenji
Ito, Kengo
Nakamura, Akinori
Senda, Michio
Day, Theresa A.
Burnham, Samantha C.
Iaccarino, Leonardo
Pontecorvo, Michael J.
Hansson, Oskar
Iwatsubo, Takeshi
Funding for this research was provided by:
Japanese Agency for Medical Research and Development (JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001, JP19dk0207048h001)
National Institute of Aging (R01AG083740, R01AG083740)
Alzheimer’s Association (SG-23-1061717, SG-23-1061717)
Swedish Research Council (2022-00775, 2022-00775)
Article History
Received: 12 March 2024
Accepted: 29 April 2024
First Online: 23 May 2024
Declarations
:
: The study was conducted in accordance with the tenets of the Declaration of Helsinki and subsequent amendments, and all participants provided written informed consent. The J-TRC study is approved by the ethical review boards of the University of Tokyo and each collaborating institute, and BioFINDER is approved by the Regional Ethics Committee in Lund, Sweden.
: YN has received consultancy/speaker fees from Eisai, and Eli Lilly and Company. SJ reported grants from the Swedish Alzheimer Foundation outside the submitted work. TK has received speaker fees from Eisai, PDR Pharmaceutical, and Nihon Medi-Physics. AI has acquired research support from Janssen pharmaceuticals, Fujirebio, Sysmex, Chugai Pharmaceuticals, Kobayashi pharmaceuticals, Dream medical partners, Sound Innovation, and SONY, and received consultancy/speaker fees from Eisai, Daiichi Sankyo, Kowa, HU frontier, Janssen pharmaceuticals, Eli Lilly and Company, MSD, Biogen, IQVIA, owns stock of Eisai. IR has received speaker fees from Eisai. TIk has received research grant for the institution from Fujirebio, Eli Lilly and Eisai. In the past 3 years, TIk has received consultancy/speaker fees from Eisai, Eli Lilly, Fujirebio, Novo Nordisk, Daiichi Sankyo, Chugai, Roche and FDR Pharma. KIs has acquired research support from GE Healthcare and Nihon Medi-Physics, consultancy/speaker fees from Nihon Medi-Physics, Eisai, and Eli Lilly. KIt has received consultancy/speaker fees from Eisai, and Eli Lilly. AN has received speaker fee from Eisai, Towa, PDRadiopharma and Nihon Medi-Physics. MS has acquired research support (for the institution) from Avid Radiopharmaceuticals, Eli Lilly Japan, GE Healthcare, Cerveau Technologies, Meilleur Technologies, Eisai, Biogen, Janssen Pharma, and Sumitomo Heavy Industries, as well as received consultancy fees (for the institution) from Eli Lilly Japan. TAD, SB, LI and MP are full-time employees and minor stockholders of Eli Lilly and company. OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly and Company, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, OH has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly and Company, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. TIw has received consultancy/speaker fee from Biogen, Eisai, Eli-Lilly and Company, and Roche/Chugai. No other disclosures were reported.